Why a young, unemployed boy has become a trailblazer in the quest to cure Alzheimer’s
A 5-year-old boy with Alzheimer’s disease was one of the first to get a patent on a cure for the disease.
The boy’s father was a veteran of the Iraq war, and his parents thought their son could help them get back to normal lives.
But the boy, Christopher, had trouble keeping up with his schoolwork and homework, and by the time he was a teenager, his cognitive function was severely impaired.
His father said his son would often cry, and Christopher struggled with anxiety.
Christopher was diagnosed with the rare disease in 2011 and began living with a wheelchair at home.
He spent his free time reading, and in 2013 he wrote the first patent application for an Alzheimer’s drug.
It is now in the hands of pharmaceutical company AstraZeneca, and he’s a pioneer of the new field of Alzheimer’s treatment.
Chris’ father, Mark, is a retired teacher and is a former head of a private charter school in Texas.
They say Christopher was the only child they knew who struggled with his mental illness.
They have been living with the condition since then, but Christopher has been unable to attend school or even speak.
He started his own company, Riverview, and began researching treatments for Alzheimer’s.
He said his research helped him understand that the disease is not a disability, but a disease that must be treated.
He said he has been diagnosed with mild cognitive impairment, which means his cognitive abilities are fine.
His wife and son are very supportive.
The couple said they have spent the past three years searching for ways to treat Christopher, and they are hoping to start their own treatment company soon.
“I think we have found something that we can live with,” Mark said.
“It’s been a huge blessing for us.”
Riverview, which is based in Houston, specializes in treating young adults with Alzheimer.
They’re currently testing a drug to treat mild cognitive dysfunction, and have started to treat adults with mild dementia.
They are also researching the use of a drug called Risperdal.
The company says their drugs are less invasive than standard medications and are safe and effective for most patients.
Mark and his wife are in talks with other companies about doing the same.
They’ve been in touch with some of the big names in the field, like Astra Zeneca and Merck.
They hope their drugs will eventually become available to people with Alzheimer, but the biggest hurdles remain.
Chris is the youngest of six children.
He is the first of five children.
His parents have been unemployed since he was about 10 years old, and now they’re working two jobs to pay the bills.
Christopher’s father works part-time in the military and spends his free days doing chores.
“We’re very fortunate.
We’re doing fine, but we’re not wealthy.
We’ve never been able to save money for college,” Christopher said.
Chris also is the only boy in the family who has not received a diagnosis of the rare genetic disorder, which affects just a handful of people in the U.S.
AstraZeneca says it’s been working with Riverview since the beginning.
“Chris is a pioneer in the Alzheimer’s field,” the company said in a statement.
“His work has been groundbreaking in advancing treatment approaches for the disorder, and we look forward to working with him as his treatment is developed.”